ENTRUST-GLOBAL
14.6.2021 21:15:03 CEST | Business Wire | Press release
The Blue Sky Aviation strategy managed by EnTrust Global (“EnTrust”), a leading alternative asset management firm, and funds managed by Strategic Value Partners, LLC and its affiliates ("SVPGlobal"), a global investment firm, have today announced the completion of the acquisition of the Aviation Investment and Asset Management business from DVB Bank Group, resulting in the formation of Deucalion Aviation Limited (“Deucalion” or the “Company”). Deucalion is an innovative global platform with world class aviation expertise and the ability to invest across the capital spectrum to provide solutions to airlines and aviation investors.
Led by Jon Skirrow and Stephan Sayre, with the support of EnTrust Global and SVPGlobal, Deucalion is a servicer for over 170 aircraft on lease to 86 airlines with clients including banks, investors, financiers and lessors.
Jon Skirrow, Co-CEO & COO said: “This new investment creates a platform with collaboration at its heart to enable us to continue and expand our world-leading services to airlines and investors”.
Stephan Sayre, Co-CEO & CIO added: “EnTrust and SVPGlobal share our vision to provide transformational financing and investment solutions. Together, we will be able to significantly strengthen our offering of innovative financing solutions to airline and leasing clients globally in the current environment”.
Victor Khosla, Founder & CIO of SVPGlobal, said: “Deucalion is a top-tier aviation platform with an experienced management team, a global footprint, and an impressive track record that spans almost two decades of managing complex aviation projects. We look forward to working with the Deucalion team as we continue to capitalize on the current market opportunity.”
John Morabito, Senior Managing Director and Portfolio Manager of EnTrust Global’s Blue Sky Aviation strategy, said: “The Deucalion team, led by Jon and Stephan, has extensive institutional knowledge and experience in the aviation industry. By combining our groups’ strengths, relationships, and capabilities, we are positioned to provide differentiated financing solutions to the global aviation industry.”
About Deucalion Aviation Limited
Deucalion Aviation Limited is a servicer for over 170 aircraft on lease to 86 airlines with clients including banks, investors, financiers and lessors and is headquartered in London with offices in Europe, Asia and America. Led by Jon Skirrow and Stephan Sayre, the Deucalion team is composed of over 45 marketing, commercial finance, origination and technical professionals with experience throughout multiple aviation cycles. www.deucalion.com
About EnTrust Global
EnTrust Global is a leading alternative asset management firm with approximately $19.5 billion in total assets.* Co-founded in 1997 by Chairman and CEO Gregg S. Hymowitz, the firm manages assets for over 500 institutional investors representing 48 countries and has approximately $11 billion in customized strategic partnerships. EnTrust Global offers a diverse range of alternative investment opportunities across strategies, including private debt and real assets as well as opportunistic co-investments and direct investments. EnTrust Global has 10 offices worldwide and is headquartered in New York and London.
*As of March 31, 2021. Based on estimates and includes assets under advisement and mandates awarded but not yet funded.
About Strategic Value Partners
SVPGlobal is a global investment firm focused on special situations and private equity opportunities with more than $15 billion in assets under management. The firm, established by Victor Khosla in 2001, uses a combination of sourcing, financial, and operational expertise. SVP has 128 employees, including 50 investment professionals, across its main offices in Greenwich (CT), London and Tokyo.
Learn more at www.svpglobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom